On April 28, 2025 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), reported data from preclinical studies of three exatecan-based antibody drug conjugates (ADCs) targeting Claudin-6 (CLDN6), prostate-specific membrane antigen (PSMA), and Alanine, Serine, Cysteine Transporter 2 (ACST2) as presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025 (Press release, ADC Therapeutics, APR 28, 2025, View Source [SID1234652278]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe these presentations demonstrate the strong potential of our exatecan-based ADCs to treat a wide range of solid and hematologic cancers beyond lymphoma. The data from the oral presentation of our CLDN6-targeted ADC show its potential, both as a single agent and in combination, to treat ovarian and non-small cell lung cancers," said Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics. "Our additional presentations showcase compelling data validating the potency and tolerability of our PSMA-targeting and ASCT2-targeting ADCs."

Data from the preclinical investigation of ADCT-242, a novel exatecan-based ADC targeting CLDN6, were presented in an oral presentation titled, "Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single agent or in combination in ovarian and non-small lung cancer models." Key highlights from this presentation include:

ADCT-242 demonstrated potent anti-tumor activity in vivo in PA-1 and OVCAR-3 xenograft models with medium CLDN6 expression
CLDN6-dependent anti-tumor activity of ADCT-242 was observed in lung patient-derived tumor models
ADCT-242 was tolerated in mice or cynomolgus monkeys at doses up to 150 mg/kg or 40 mg/kg, respectively, indicative of a good therapeutic index
Data from the preclinical investigation of ADCT-241, a novel PSMA-targeting ADC, were presented in a poster presentation titled, "Preclinical Development of ADCT-241, a Novel Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the Treatment of Prostate Cancer." The data demonstrated antitumor activity in both xenograft and patient-derived PSMA-expressing prostate cancer models as well as synergy with enzalutamide. ADCT-241 was well tolerated in both rats and cynomolgus monkeys.

Data from the preclinical investigation of HuB14-VA-PL2202, a novel ASCT2-targeting ADC, were presented in a poster presentation titled, "HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers." The data demonstrated potent and specific in vitro and in vivo antitumor activity of HuB14-VA-PL2202 in ASCT2-positive solid and hematological cancer cell lines, and HuB14-VA-PL2202 was well-tolerated in cynomolgus monkeys.